0.41
-0.01490001(-3.51%)
Currency In USD
| Previous Close | 0.42 |
| Open | 0.43 |
| Day High | 0.45 |
| Day Low | 0.39 |
| 52-Week High | 3.33 |
| 52-Week Low | 0.37 |
| Volume | 406,851 |
| Average Volume | 309,706 |
| Market Cap | 14.09M |
| PE | -1.78 |
| EPS | -0.23 |
| Moving Average 50 Days | 0.72 |
| Moving Average 200 Days | 1.2 |
| Change | -0.01 |
If you invested $1000 in Jupiter Neurosciences, Inc. (JUNS) since IPO date, it would be worth $0 as of March 11, 2026 at a share price of $0.409. Whereas If you bought $1000 worth of Jupiter Neurosciences, Inc. (JUNS) shares 1 year ago, it would be worth $74.55 as of March 11, 2026 at a share price of $0.409.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Jupiter Neurosciences to Present at BIO Investment and Growth Summit 2026
GlobeNewswire Inc.
Mar 02, 2026 1:00 PM GMT
Advancing FDA-Cleared Phase IIa Parkinson’s Program Targeting Neuroinflammation Dual-Path Strategy Combines Clinical Development with Revenue-Generating Nugevia™ JUPITER, FL, March 02, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: J
Jupiter Neurosciences Invited to Present Clinical and Commercial Progress at Investor Dinner at Mar-a-Lago
GlobeNewswire Inc.
Feb 25, 2026 1:30 PM GMT
Jupiter Neurosciences, Inc. Jupiter Neurosciences Invited to Present Clinical and Commercial Progress at Investor Dinner at Mar-a-Lago JUPITER, FL, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "
Jupiter Neurosciences Amends Yorkville Installment Provisions to Align Capital With Clinical and Commercial Execution
GlobeNewswire Inc.
Feb 23, 2026 2:30 PM GMT
Repayment Commencement Deferred to April 1, 2026 Core Economic Terms of $6.0 Million Financing Remain Unchanged JUPITER, FL, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company focus